In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Lifeward (LFWD – Research Report), with a price target of $13.00.
Swayampakula Ramakanth’s rating is based on Lifeward’s promising growth prospects and strategic initiatives. The company has demonstrated a strong pipeline with plans to expand the market reach of its ReWalk Personal product among patients covered by various insurance providers. Despite facing some delays in CMS reimbursement, Lifeward anticipates a more efficient processing period in the future, which could enhance its market penetration.
Lifeward’s recent partnerships are also pivotal in its growth strategy. The collaboration with MYOLYN aims to improve patient access to the Myocycle FES Cycling Therapy System, while the partnership with CorLife is expected to streamline the distribution of ReWalk Personal Exoskeletons. These agreements are likely to drive product adoption and contribute to Lifeward’s revenue growth. Additionally, the company’s financial performance in 4Q24, with a significant revenue increase, supports the positive outlook for 2025 and beyond.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFWD in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com